Comparison between Symbiotec Pharmalab IPO and WOG Technologies IPO.
Symbiotec Pharmalab IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while WOG Technologies IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Symbiotec Pharmalab IPO is up to ₹2,180.00 Cr whereas the issue size of the WOG Technologies IPO is up to ₹0.00 Cr. The final issue price of Symbiotec Pharmalab IPO is and of WOG Technologies IPO is .
| Symbiotec Pharmalab IPO | WOG Technologies IPO | |
|---|---|---|
| Face Value | ₹2 per share | ₹10 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹150.00 Cr | up to ₹3,750.00 Cr |
| OFS Issue Size | 0 shares | 43,28,000 shares |
| OFS Issue Size (Amount) | up to ₹2,030.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 0 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹2,180.00 Cr | up to ₹0.00 Cr |
Symbiotec Pharmalab IPO opens on , while WOG Technologies IPO opens on . The closing date of Symbiotec Pharmalab IPO and WOG Technologies IPO is , and , respectively.
Symbiotec Pharmalab IPO P/E ratio is , as compared to WOG Technologies IPO P/E ratio of .
| Symbiotec Pharmalab IPO | WOG Technologies IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Symbiotec Pharmalab Ltd.'s revenue increased by 5% and profit after tax (PAT) dropped by 3% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)WOG Technologies Ltd.'s revenue increased by 101% and profit after tax (PAT) rose by 1487% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 34.47 | 88.62 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 12.66% | 71.79% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 11.80% | 51.32% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 11.79% | 39.95% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Symbiotec Pharmalab IPO Retail Individual Investors (RII) are offered 0 shares while in WOG Technologies IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Symbiotec Pharmalab IPO and 0 shares in WOG Technologies IPO.
| Symbiotec Pharmalab IPO | WOG Technologies IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 0 shares | 0 shares |
| NII | 0 shares | 0 shares |
| RII | 0 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 0 shares |
Symbiotec Pharmalab IPO subscribed in total, whereas WOG Technologies IPO subscribed .
